BDBM268081 4-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-2-[(3R)-3-methylmorpholin-4-yl]-8-(1H-pyrazol-5-yl)-1,7-naphthyridine::US9549932, 113
SMILES: CCn1nc(C)cc1-c1cc(nc2c(nccc12)-c1ccnn1C1CCCCO1)N1CCOC[C@H]1C
InChI Key: InChIKey=NCZOREXJRVPTQO-OEPVSBQMSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Serine/threonine-protein kinase ATR (Homo sapiens (Human)) | BDBM268081 (4-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-2-[(3R)-3-met...) | PDB Reactome pathway UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.71 | n/a | n/a | n/a | n/a | 7.0 | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description To determine of binding activity of the test compounds, full-length human ATR protein was expressed and purified together with ATRIP as described abo... | US Patent US9549932 (2017) BindingDB Entry DOI: 10.7270/Q27S7QSC | |||||||||||
More data for this Ligand-Target Pair |